ebola
viru
ebov
marburg
viru
marv
envelop
rna
virus
belong
famili
filovirida
appear
electron
microscop
threadlik
filament
genu
ebolaviru
includ
five
ebov
ebov
caus
agent
current
outbreak
three
ebolavirus
includ
ebov
caus
ebola
viru
diseas
evd
clinic
character
sever
hemorrhag
fever
human
fatal
rate
first
three
ebov
outbreak
indigen
democrat
republ
congo
formerli
known
zair
sudan
case
identifi
african
countri
sinc
addit
case
identifi
late
largest
outbreak
ebov
hemorrhag
fever
start
west
africa
epidem
start
republ
guinea
initi
prefectur
decemb
case
discov
soon
sierra
leon
liberia
nigeria
one
case
seneg
outbreak
least
identifi
suspect
case
confirm
death
accord
world
health
organ
write
sever
studi
consid
differ
strategi
stop
ebov
infect
vitro
vivo
develop
antivir
small
molecul
antisens
technolog
monoclon
antibodi
cocktail
zmapp
addit
select
estrogen
receptor
modul
exampl
clomiphen
toremifen
ion
channel
blocker
exampl
verapamil
amiodaron
adenoviru
vesicular
stomat
vsv
human
parainfluenzabas
vaccin
well
vaccin
base
viruslik
particl
prepar
demonstr
potenti
efficaci
current
review
describ
structur
viru
natur
diseas
current
advanc
develop
therapeut
ebola
viru
marv
belong
filovirida
famili
envelop
virus
order
mononegaviral
character
filament
morpholog
filovirus
known
major
caus
hemorrhag
fever
human
nonhuman
primat
filament
morpholog
virus
led
name
filovirida
deriv
latin
word
filum
mean
filament
genu
ebolaviru
includ
five
speci
bundibugyo
ebolaviru
bdbv
sudan
ebolaviru
sudv
forest
ebolaviru
tafv
previous
known
cote
divoir
ebolaviru
reston
viru
restv
ebov
formerli
known
zair
ebolaviru
figur
sudv
ebov
appear
involv
known
outbreak
pathogen
restv
tafv
known
evdcaus
virus
ebov
consid
danger
involv
largest
number
outbreak
includ
outbreak
restv
caus
fatal
hemorrhag
diseas
nonhuman
primat
report
involv
human
diseas
far
base
genet
similar
ebolavirus
close
relat
marburgvirus
viral
glycoprotein
gp
gene
sequenc
major
determin
phylogenet
classif
filovirus
ebov
marv
differ
approxim
genom
level
amino
acid
level
differ
gp
gene
organ
report
ebov
marv
five
known
speci
genu
ebolaviru
differ
nucleotid
amino
acid
level
respect
indic
bdbv
rebov
sudv
tafv
ebov
distinct
repres
differ
speci
despit
differ
ebolaviru
speci
show
degre
genet
stabil
genet
stasi
suggest
associ
particular
host
genet
variat
way
evolut
adapt
natur
host
within
order
mononegaviral
base
extent
sequenc
homolog
nterminu
rnadepend
rna
polymeras
filovirus
consid
similar
paramyxovirus
rhabdovirus
filovir
genom
consist
nonseg
neg
singlestrand
linear
rna
molecul
make
total
virion
mass
genom
size
approxim
kb
marv
ebov
viral
genom
made
seven
gene
arrang
end
order
nucleoprotein
np
ii
viral
structur
protein
iii
iv
gp
v
vi
vii
rnadepend
rna
polymeras
gene
l
end
genom
highli
conserv
noncod
nucleotid
sequenc
function
promot
transcript
replic
filovirus
addit
signal
packag
viral
genom
filovirus
includ
ebov
produc
seven
structur
protein
encod
viral
genom
four
seven
protein
np
l
known
directli
bind
negativesens
rna
genom
form
ribonucleoprotein
complex
remain
three
structur
protein
includ
gp
major
membran
spike
protein
major
minor
matrix
protein
respect
protein
interact
viral
envelop
nucleocapsid
serv
bridg
molecul
addit
nonstructur
solubl
gp
precursor
protein
produc
subsequ
cleav
sgp
delta
peptid
recent
studi
show
protein
capabl
form
filament
viral
particl
coexpress
gp
protein
gp
spike
local
surfac
virion
suggest
protein
control
virion
shape
morpholog
minor
matrix
protein
uniqu
filovirus
play
role
bud
assembl
due
associ
lipid
membran
togeth
np
enhanc
bud
releas
viruslik
particl
vlp
requir
assembl
format
function
ribonucleoprotein
complex
addit
describ
regul
viral
transcript
replic
report
bind
thu
prevent
nuclear
accumul
tyrosin
phosphoryl
lead
final
inhibit
ifn
signal
polymeras
cofactor
associ
ebov
rna
genom
act
type
ifn
antagonist
express
ebov
reviv
replic
defect
influenza
viru
lack
protein
wherea
ebov
protein
could
furthermor
inhibit
product
trigger
poli
c
mutant
influenza
viru
infect
sendai
viru
infect
suggest
ebov
act
ifn
antagonist
quit
similar
influenza
protein
report
ebov
inhibit
interferon
product
bind
mask
ebov
dsrna
ii
inhibit
phosphoryl
interferon
regulatori
factor
irf
impair
local
nucleu
addit
abil
block
ifn
product
show
abil
counteract
block
antivir
respons
target
cell
ebola
viru
gp
gene
transcrib
translat
produc
two
protein
first
small
polypeptid
product
gp
gene
sgp
second
fulllength
larger
gene
product
gp
produc
insert
adenosin
residu
transcript
rna
edit
gp
process
furin
enzym
subtilisinkexinlik
convertas
local
transgolgi
polybas
cleavag
site
matur
protein
nterminu
subunit
mr
ctermin
subunit
mr
link
disulfid
bond
subunit
contain
sever
nglycosyl
oglycosyl
matur
protein
exist
homotrim
surfac
viral
particl
trimer
mediat
deadli
infect
ebov
avian
flu
transmit
anim
human
human
ebov
infect
typic
occur
rural
set
possibl
contact
infect
nonhuman
primat
bodi
fluid
evid
strongli
suggest
fruit
bat
natur
reservoir
ebov
africa
fruit
bat
hypsignathu
monstrosu
epomop
franqueti
myonycteri
torquata
found
natur
host
ebov
addit
nonhuman
primat
ape
monkey
infect
bat
drop
partial
eaten
fruit
repres
like
mean
viru
transmiss
human
start
mammal
like
gorilla
ape
monkey
duiker
feed
partial
eaten
fruit
acquir
infect
transmit
human
guinea
believ
current
outbreak
start
child
play
insectivor
bat
coloni
angolan
freetail
bat
near
villag
earli
outbreak
democrat
republ
congo
usual
involv
bat
reservoir
around
subterranean
gold
mine
peopl
healthcar
set
close
contact
secret
infect
patient
involv
burial
infect
dead
bodi
higher
risk
ebov
infect
transmiss
ebov
occur
close
contact
skin
secret
individu
suffer
activ
infect
urin
saliva
sweat
fece
vomitu
breast
milk
semen
viruscontamin
object
transmit
infect
well
infect
ebov
need
rel
high
viral
dose
pfug
transmiss
like
occur
onset
symptom
incub
period
ebov
onset
symptom
rang
day
ebovent
bodi
small
skin
lesion
mucou
membran
reach
blood
stream
evid
aerosol
transmiss
although
exclud
ebola
viru
infect
quickli
progress
lethal
hemorrhag
diseas
human
nonhuman
primat
filovir
hemorrhag
fever
hf
consid
danger
sever
form
viral
hemorrhag
fever
intens
clinic
manifest
hemorrhag
coagul
disord
shock
hepat
failur
prodrom
symptom
includ
chill
fever
headach
malais
myalgia
progress
diseas
sever
diseas
specif
symptom
experienc
gastrointestin
symptom
vomit
abdomin
pain
diarrhea
respiratori
cough
chest
pain
short
breath
vascular
symptom
conjunctiv
hemorrhag
postur
hypotens
extrem
edema
neurolog
symptom
character
sever
headach
confus
coma
death
filovir
infect
usual
result
hypovolem
septic
shock
consequ
sever
complic
increas
permeabl
blood
vessel
hypotens
coagul
problem
multiorgan
failur
focal
tissu
destruct
humor
respons
detect
around
day
postinfect
influenc
surviv
death
patient
ebola
viru
infect
wide
rang
tissu
includ
skin
mucou
membran
intern
organ
ebov
tissu
effect
liver
focal
necrosi
promin
lead
dissemin
intravascular
coagul
dic
spleen
lymph
node
show
extens
follicular
necrosi
necrot
debri
infect
lung
show
interstiti
edema
hemorrhag
clear
alveolar
damag
addit
heart
show
edema
focal
necrosi
primari
site
viral
replic
believ
monocyt
macrophag
dendrit
cell
dc
involv
viral
transloc
lymph
node
lymphat
endotheli
dysfunct
lead
wide
rang
vascular
effect
lead
hemorrhag
increas
vascular
permeabl
ebola
viru
gp
viral
class
membran
fusion
protein
quit
similar
prototyp
envelop
protein
influenza
viru
hemagglutinin
organ
function
subunit
contain
receptorbind
domain
mediat
interact
cognat
receptor
host
cell
interact
preserv
conform
transmembran
subunit
subunit
contain
machineri
requir
fusion
viral
membran
host
cell
membran
subunit
consist
three
domain
nterminu
half
highli
conserv
form
base
interact
extens
maintain
prefus
state
ii
head
contain
receptorbind
sequenc
iii
cterminu
domain
compris
highli
glycosyl
region
name
glycan
cap
mucin
domain
figur
gp
fold
mediat
glycan
cap
addit
glycan
cap
report
crucial
role
entri
mucin
domain
may
requir
ebovgp
depend
pseudoviru
entri
vitro
propos
mediat
viral
adhes
specif
cell
type
play
role
evas
immun
respons
mask
key
neutral
epitop
base
glycan
cap
connect
short
loop
transmembran
fusion
subunit
contain
ntermin
hydrophob
intern
fusion
peptid
addit
ntermin
ctermin
helic
heptad
repeat
figur
close
interact
trigger
gp
process
viral
entri
drive
fusion
viral
host
membran
ebola
viru
infect
mani
cell
type
broad
mammalian
host
cell
tropism
broad
host
cell
rang
suggest
ebov
use
either
ubiquit
express
receptor
cell
type
viru
recogn
bind
sever
surfac
receptor
express
differ
host
cell
evid
sever
studi
support
latter
scenario
ctype
lectin
exampl
dcsign
lsign
highli
express
surfac
mani
cell
type
shown
mediat
entri
ebov
entri
virus
howev
import
note
cell
permiss
ebov
infect
express
ctype
lectin
role
natur
infect
remain
determin
moreov
sever
studi
shown
dcsignlsign
lsectin
hmgl
famili
receptor
may
involv
attach
ebov
host
cell
surfac
none
cellular
factor
prove
essenti
viral
entri
tcell
immunoglobulin
mucin
domain
protein
tcell
costimulatori
molecul
phosphatidylserin
receptor
identifi
candid
cell
surfac
receptor
ebov
highli
express
human
epitheli
cell
includ
airway
epithelium
known
target
ebov
fact
permiss
cell
macrophag
dc
express
suggest
ebov
use
receptor
gain
entri
immun
cell
role
ebov
entri
vivo
remain
determin
host
protein
niemannpick
recent
shown
import
receptor
involv
ebov
viru
entri
larg
express
cell
known
local
late
endosom
lysosom
lysosom
efflux
lowdens
lipoprotein
cholesterol
ldl
mediat
part
studi
show
small
molecul
inhibitor
block
ebov
entri
vitro
furthermor
defici
hamster
cell
line
permiss
ebov
studi
suggest
requir
may
indispens
ebov
entri
role
ebov
entri
complet
distinct
function
cholesterol
metabol
studi
show
cleav
uncleav
ebovgp
bind
late
endosom
bind
depend
suggest
prime
gp
cystein
proteas
requir
bind
homotyp
fusion
vacuol
proteinsort
complex
aid
fusion
endosom
lysosom
might
involv
viral
entri
essenti
follow
attach
surfac
receptor
viru
intern
via
macropinocytosislik
mechan
process
involv
format
plasma
membran
ruffl
larg
particl
size
ebov
might
suggest
use
macropinocytosi
intern
use
rout
depend
gp
interact
rather
virion
size
lectin
report
trigger
macropinocytosi
studi
shown
ebovgp
pseudotyp
virus
coloc
late
endosom
domin
neg
inhibitor
reduc
infect
suggest
deliveri
late
endosom
crucial
viral
entri
howev
yet
known
whether
viru
deliv
genom
cytoplasm
directli
late
role
caveola
ebov
entri
remain
unclear
studi
need
show
whether
caveola
involv
ebov
entri
clathrinmedi
endocytosi
implic
ebov
entri
howev
base
evid
differ
studi
ebov
may
use
differ
pathway
gain
entri
host
cell
depend
cell
type
viral
isol
possibl
viral
load
gener
ebovgp
class
viral
gp
prime
fusion
furin
cleavag
singl
site
within
viru
produc
cell
cleavag
expos
peptid
trigger
fusion
viral
host
cell
membran
cleavag
gp
furin
dispens
vitro
vivo
block
affect
infect
viru
led
conclus
furinmedi
cleavag
gp
protein
virusproduc
cell
drive
fusion
inde
driven
host
endosom
cystein
proteas
target
cell
cathepsin
b
catb
cathepsin
l
catl
cystein
proteas
identifi
host
proteas
involv
ebovgp
process
structur
biochem
evid
suggest
cleavag
loop
connect
base
head
subunit
expos
underli
fusion
loop
allow
function
fusion
process
possibl
cleavag
ebovgp
cystein
proteas
unmask
bind
site
unknown
receptor
possibl
role
promot
fusion
higher
bind
catl
treat
ebovgp
pseudotyp
virion
target
cell
support
specul
lack
preexposur
postexposur
therapeut
intervent
ebov
lethal
ebov
infect
necessit
develop
antivir
protect
vaccin
formalinfix
heatinactiv
virusbas
vaccin
produc
soon
outbreak
protect
guinea
pig
nonhuman
primat
howev
protect
report
studi
inconsist
elicit
immun
respons
insuffici
protect
baboon
lethal
dose
ebov
sever
studi
shown
tremend
effort
develop
subunit
vaccin
ebov
sinc
earlier
studi
led
conclus
mice
guinea
pig
protect
speci
nonhuman
primat
need
mount
robust
immun
respons
achiev
protect
howev
studi
publish
natur
show
dnabas
immun
boost
adenovir
vector
encod
viral
protein
gener
cellular
humor
immun
cynomolgu
macaqu
remain
asymptomat
month
detect
viru
initi
challeng
unvaccin
anim
die
less
week
controversi
result
obtain
vaccin
studi
nonhuman
primat
indic
extens
research
requir
develop
vaccin
provid
complet
protect
ebov
septemb
experiment
vaccin
two
ebov
ebov
sudv
jointli
develop
glaxosmithklin
nation
institut
health
start
phase
clinic
trial
administ
volunt
oxford
bethesda
mali
initi
result
promis
deriv
chimpanze
adenoviru
type
engin
express
ebovgp
sudvgp
second
vaccin
candid
rvsvebov
first
develop
public
health
agenc
canada
merck
inc
rvsvebov
effect
ebov
nonhuman
primat
vaccin
candid
develop
johnson
johnson
pharmaceut
chines
govern
approv
clinic
trial
acut
infect
instantan
protect
measur
includ
antivir
small
molecul
passiv
antibodi
therapi
may
promis
combat
ebov
hf
current
outbreak
sever
promis
treatment
consid
develop
current
soon
undergo
clinic
trial
one
consid
treatment
transfus
whole
blood
purifi
serum
ebov
survivor
identifi
possibl
treatment
earli
decemb
first
clinic
trial
therapi
includ
patient
start
etern
love
win
africa
treatment
center
liberia
sponsor
gate
foundat
collabor
nation
health
author
clinic
trial
soon
start
guinea
sierra
leon
zmapp
combin
three
human
murin
monoclon
antibodi
develop
mapp
biopharmaceut
inc
produc
tobacco
plant
mice
zmapptreat
anim
surviv
prove
highli
effect
trial
involv
rhesu
macaqu
monkey
zmapp
use
treat
patient
current
west
africa
outbreak
howev
efficaci
remain
determin
combin
small
interf
rna
sirna
ebovl
formul
stabl
nucleic
acid
lipid
particl
show
protect
rhesu
monkey
lethal
ebov
infect
drug
formul
use
lipid
nanoparticl
technolog
tekmira
pharmaceut
corp
name
tkmebola
phase
clinic
trial
involv
healthi
volunt
initi
quickli
suspend
due
advers
side
effect
howev
later
food
drug
administr
approv
use
tkmebola
emerg
situat
sever
small
molecul
inhibitor
viral
replic
entri
develop
differ
group
ebov
antivir
favipiravir
also
known
avigan
chemic
defin
pyrazinecarboxamid
deriv
initi
develop
japan
treat
influenza
infect
effect
mous
model
ebov
infect
favipiravir
show
inhibitori
activ
influenza
viru
west
nile
viru
yellow
fever
viru
foot
mouth
diseas
viru
addit
flavivirus
arenavirus
bunyavirus
alphavirus
activ
enterovirus
rift
valley
viru
also
document
favipiravir
inhibit
viral
rnadepend
rna
polymeras
adenosin
nucleosid
analog
broadspectrum
antivir
drug
initi
develop
biocryst
pharmaceut
hepat
c
current
test
ebov
unit
state
armi
medic
research
institut
infecti
diseas
show
efficaci
wide
rang
virus
includ
bunyavirus
arenavirus
paramyxovirus
coronavirus
flavivirus
protect
ebov
marv
rodent
monkey
even
administ
h
postinfect
brincidofovir
anoth
antivir
drug
activ
ebov
well
cytomegaloviru
adenoviru
smallpox
vitro
anim
model
set
new
compound
develop
filovirus
includ
ebov
varieti
newli
develop
drug
potenti
target
ebov
drug
current
approv
diseas
inhibit
ebov
vitro
anim
model
exampl
cation
amphiphil
amiodaron
dronedaron
verapamil
clomiphen
toremifen
na
channel
na
k
exchang
blocker
amilorid
na
k
atpas
inhibitor
digoxin
digitoxin
ouabain
small
molecul
target
host
cellular
protein
phosphatas
control
ebov
dephosphoryl
inhibit
ebov
replic
vitro
phosphorodiamid
morpholino
oligom
target
ebov
rna
transcript
undergo
phase
clinic
trial
addit
novel
broadspectrum
antivir
small
molecul
inhibit
entri
wide
rang
virus
includ
ebov
block
catl
describ
intervent
includ
recombin
human
activ
protein
c
rhapc
postexposur
treatment
ebov
infect
rhesu
macaqu
ii
recombin
nematod
anticoagul
protein
potent
inhibitor
tissu
factor
initi
blood
coagul
prolong
surviv
time
rhesu
macaqu
challeng
ebov
lethal
dose
previous
describ
effort
demonstr
antiebov
drug
within
reach
ebov
epidem
may
control
near
futur
figur
recent
outbreak
start
guinea
highlight
import
develop
prevent
therapeut
intervent
protect
futur
outbreak
high
fatal
ebov
infect
addit
exist
bat
primari
anim
reservoir
nonhuman
primat
intermedi
carrier
viru
make
diseas
prevent
treatment
complex
process
sever
studi
report
develop
passiv
immunotherapi
form
antibodi
small
molecul
antivir
inhibitori
activ
ebov
infect
vitro
anim
model
infect
consider
number
develop
antivir
current
test
efficaci
safeti
clinic
trial
suggest
potent
